Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Skin & Hair
Research dose range
Standard research range
2 - 3 mg
The most commonly documented daily dose — GHK-Cu and BPC-157 both land within their own solo ranges at this level.
Research focus
Skin remodeling + local/systemic tissue repair
Observed window
BPC-157 effects often noticed by week 2; GHK-Cu skin changes by weeks 3-4
Administration
Daily
Primary pathway
Collagen/ECM remodeling (GHK-Cu), VEGF/Angiogenesis (BPC-157), G-actin sequestration (TB-500)
Three mechanisms, three real research trails: Pickart & Margolina (2018) on GHK-Cu's regenerative signaling, Vasireddi et al. and Lee & Burgess (2025) on BPC-157's repair profile, Grant et al. (1999) on TB-500's angiogenic reach. The 5:1:1 ratio bringing them together in one vial. For research use only.
MANFAAT PROTOKOL
◆
GHK-Cu drives collagen synthesis and extracellular matrix remodeling — the dominant compound in this blend by mass, and the one that governs cycle length.
◆
BPC-157 supports new blood vessel growth right at the site of injury, while TB-500 helps repair cells migrate to where they're needed.
◆
The 5:1:1 ratio isn't arbitrary — it's built so each compound's effective dose lands together in a single injection, balancing GHK-Cu's higher-mass requirement against BPC-157 and TB-500's lower thresholds.
SAINS
GLOW combines three peptides targeting different layers of the same biology. GHK-Cu, the dominant compound by mass, drives collagen, elastin, and copper-dependent tissue remodeling. BPC-157 supports local angiogenesis and repair; TB-500 helps cells migrate toward damaged tissue systemically.
The 5:1:1 ratio is intentional — GHK-Cu is effective at higher absolute doses, while BPC-157 and TB-500 work at smaller amounts, so the blend is weighted to bring each into range at once. That holds cleanly for GHK-Cu and reasonably for BPC-157. TB-500 still lands below where its own solo protocols typically start — the tradeoff for one injection instead of three.
YANG DIHARAPKAN
Typically by week 2. Skin quality changes from GHK-Cu tend to follow around weeks 3-4. This runs as a cycle, not continuously — 4-8 weeks on, matched by time off; GHK-Cu's copper handling generally sets the ceiling on cycle length.
CATATAN PROTOKOL
50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 per vial (5:1:1 ratio). For research use only. Full documentation included with every order.
FAQ
Same three-peptide base — GHK-Cu, BPC-157, TB-500 — without KPV, the dedicated anti-inflammatory layer KLOW adds.
Mostly — GHK-Cu and BPC-157 land close to their own solo ranges. TB-500 doesn't; see the note below the dose table.
